Skip to main content
. 2022 Feb 7;12:834288. doi: 10.3389/fonc.2022.834288

Figure 3.

Figure 3

Clinical outcomes of the BCL patients following the infusion of CD19/CD22 dual-targeted CAR T-cells. A patient with a high-risk NGLDM_ContrastPET (> 0.468) and positive-DE showed progression after 5 months and died 9 months after CAR T-cell therapy (A, B). Kaplan-Meier curves of PFS (C) and OS (D).